| Dr Philippe Paci, MDCM | |
|
5171 S Cottonwood St Ste 210, Murray, UT 84107-5718 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Dr Philippe Paci |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 11 Years |
| Location | 5171 S Cottonwood St Ste 210, Murray, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003462136 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 12433934-1205 (Utah) | Secondary |
| 204F00000X | Transplant Surgery | 12433934-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Intermountain Medical Center | Murray, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.
Research that followed more than 1.6 million Swedish men from adolescence onwards between 1968 and 2005 has shown that those who were overweight as teenagers were more likely to develop heart failure in early middle age.
Tactically, however, (former Alaska Gov. Sarah) Palin's move was pure brilliance: in but a few keystrokes she synthesized the underlying suspicion at least half of Americans have about a government role in health care delivery and created a visual metaphor from which the Obama White House and congressional Democrats still haven't fully recovered. So would it surprise you that Palin has a legitimate point? Well, sort of (John Edgell, 9/4).
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
Families with food-allergic children face a life of constant vigilance and the looming fear of life-threatening allergic reactions. This fear can have a huge impact on an entire family's life, from heightened anxiety to severe limits on their daily activities. Some families cope well with this situation, while others find it extremely stressful and difficult to manage.
› Verified 8 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.
Research that followed more than 1.6 million Swedish men from adolescence onwards between 1968 and 2005 has shown that those who were overweight as teenagers were more likely to develop heart failure in early middle age.
Tactically, however, (former Alaska Gov. Sarah) Palin's move was pure brilliance: in but a few keystrokes she synthesized the underlying suspicion at least half of Americans have about a government role in health care delivery and created a visual metaphor from which the Obama White House and congressional Democrats still haven't fully recovered. So would it surprise you that Palin has a legitimate point? Well, sort of (John Edgell, 9/4).
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
Families with food-allergic children face a life of constant vigilance and the looming fear of life-threatening allergic reactions. This fear can have a huge impact on an entire family's life, from heightened anxiety to severe limits on their daily activities. Some families cope well with this situation, while others find it extremely stressful and difficult to manage.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philippe Paci, MDCM 5171 S Cottonwood St Ste 210, Murray, UT 84107-5718 Ph: (507) 284-2511 | Dr Philippe Paci, MDCM 5171 S Cottonwood St Ste 210, Murray, UT 84107-5718 Ph: (507) 284-2511 |
News Archive
The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent.
Research that followed more than 1.6 million Swedish men from adolescence onwards between 1968 and 2005 has shown that those who were overweight as teenagers were more likely to develop heart failure in early middle age.
Tactically, however, (former Alaska Gov. Sarah) Palin's move was pure brilliance: in but a few keystrokes she synthesized the underlying suspicion at least half of Americans have about a government role in health care delivery and created a visual metaphor from which the Obama White House and congressional Democrats still haven't fully recovered. So would it surprise you that Palin has a legitimate point? Well, sort of (John Edgell, 9/4).
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
Families with food-allergic children face a life of constant vigilance and the looming fear of life-threatening allergic reactions. This fear can have a huge impact on an entire family's life, from heightened anxiety to severe limits on their daily activities. Some families cope well with this situation, while others find it extremely stressful and difficult to manage.
› Verified 8 days ago